Literature DB >> 22327867

[Neck dissection of the residually positive neck after primary radiochemotherapy for locally advanced head and neck cancer].

H Christiansen1, R M W Rödel.   

Abstract

Entities:  

Year:  2012        PMID： 22327867     DOI： 10.1007/s00066-011-0064-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Adaptive dose painting by numbers for head-and-neck cancer.

Authors:  Fréderic Duprez; Wilfried De Neve; Werner De Gersem; Marc Coghe; Indira Madani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-17       Impact factor: 7.038

2.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

3.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

Review 4.  GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.

Authors:  Jean-Jacques Mazeron; Jean-Michel Ardiet; Christine Haie-Méder; György Kovács; Peter Levendag; Didier Peiffert; Alfredo Polo; Angels Rovirosa; Vratislav Strnad
Journal:  Radiother Oncol       Date:  2009-03-28       Impact factor: 6.280

5.  Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.

Authors:  Athanassios Argiris; Kerstin M Stenson; Bruce E Brockstein; Bharat B Mittal; Harold Pelzer; Merrill S Kies; Prathima Jayaram; Louis Portugal; Barry L Wenig; Fred R Rosen; Daniel J Haraf; Everett E Vokes
Journal:  Head Neck       Date:  2004-05       Impact factor: 3.147
  5 in total
  1 in total

1.  Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.

Authors:  C Matuschek; E Bölke; C Belka; U Ganswindt; M Henke; P Stegmaier; M Bamberg; S Welz; J Debus; A Gioules; A Voigt; G Volk; C Ohmann; T Wiegel; V Budach; M Stuschke; J Schipper; P A Gerber; W Budach
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.